Treating persons with heme malignancies in limited resources settings is extremely challenging.
Yet, this is hardly discussed in top venues or forums.
I hope you like my editorial The Underrepresented Majority now in @TheLancetHaem
https://t.co/Hckrl7ykQJ
French architect and designer Emmanuelle Moureaux's large-scale interactive installation created with thousands of coloured paper cut numerals, known as the 'Forest of Numbers' #WomensArt
Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases
@Haematologica
https://t.co/ZnBemelCWD
Received a call from a community oncologist expressing dismay that his #MDS patient now had two different classifications based on #ICC and #WHO…the reality of academic brutality is that our patients and communities end up paying the price #Thismuststop#Patientscomefirst
https://t.co/rrAFO3LR5p Link to - How I diagnose and treat #CMML@Haematologica | Comprehensive and practical approach to one of the most fascinating neoplasms | Rare diseases are not rare to those afflicted by them| #notMDS#notMPN@MayoCancerCare
👉🏻Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel @AML_Hub@ASTCT@ASH_hematology@TheEBMT https://t.co/9gI2aAV0EP
Our latest perspective:
Enhancing the Trajectories of Cancer Health Disparities Research: Improving Clinical Applications of Diversity, Equity, Inclusion, and Accessibility https://t.co/gdNkJmJURY
Drumroll please .... the International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data is now available online!!! https://t.co/Kw2lZuG6aT
#hemepath#SHupdatebyte
Proud to see our grandiose cavalcade of #ctDNA analysis in aggressive LBCLs out in @BloodJournal colors.
https://t.co/k0KhrfmKG9
🧵 Here’s what we learned from our trial by analyzing ordinary plasma samples for their extraordinary content /n
🩸TdT has been proposed to be involved in the generation of FLT3-ITD and NPM1 mutations in AML (below example of NPM1 mutated AML with FLT3-ITD mutation and TDT overexpression by IHC) #hemepath#leusm#bmtsm
"Molecular Diagnostic Outcomes from 700 Cases: What Can We Learn from a Retrospective Analysis of Clinical Exome Sequencing?". New #OpenAccess article from multiple @AMPath member authors.
Full FREE text: https://t.co/p7Dlz6epqt